This article is more than 5 years old. Information may no longer be current.

Avedro gains Canadian regulatory approval for Lasik Xtra

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WALTHAM, Mass. — A proprietary Avedro procedure combining LASIK with accelerated corneal cross-linking has been granted approval for use in Canada, according to a company press release.

The 2-minute Lasik Xtra procedure is performed in conjunction with standard LASIK to restore strength and biomechanical integrity to the cornea, the release said. It uses Avedro's KXL system for ultraviolet A radiation along with riboflavin ophthalmic solution.

"Avedro has the only cross-linking products specifically approved in Canada for performing Lasik Xtra, and we are pleased to enable this procedure for a growing number of ophthalmologists and their LASIK patients," David Muller, PhD, CEO of Avedro, said in the release.

Avedro gained the European CE mark approval for Lasik Xtra earlier this month. The procedure is not available in the United States.